Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q4 FY2021 Earnings Presentation
31 slides from Jubilant Ingrevia's earnings presentation, Jun 7, 2021
Slide 1: Financial Results Quarter Ended March 31, 2021
Financial Results Quarter Ended March 31, 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : June 07, 2021 Time : 05:00 pm IST Replay: June 07 to June 13, 2021 Dial-in: +91 22 7194 5757/ +91 22 66635757 Playback ID: 20733# 3
Slide 4: Demerger Rationale
Demerger Rationale Effective 1st February 2021, Life Science Ingredients business of Jubilant Life Sciences demerged to Jubilant Ingrevia Limited. • Demerger will facilitate in creating a simple structure with two separate pure-play entities Simplified Corporate Structure • Greater operational effic
Slide 5: Pre-Demerger Org Structure
Pre-Demerger | Organisation & Business Structure Pre-Demerger Org Structure Life Science Jubilant Life Sciences Limited Ingredients Business (Listed on NSE & BSE) At holding Company Level Jubilant Pharma Limited Jubilant Biosys Limited Jubilant Therapeutics Limited Jubilant Life Sciences Limited (JL
Slide 6: Post-Demerger Org Structure
Post-Demerger | Organisation & Business Structure Jubilant Ingrevia Limited Jubilant Pharmova Limited Jubilant Life Post-Demerger Org Structure Sciences Limited renamed as Carved out Life Science Jubilant Pharmova 100% Ingredients business to be housed Limited on Feb 1, in a separate entity named Ju
Slide 7: Chairmen's Message
Chairmen’s Message Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are glad to announce that we performed well during FY21. Despite the COVID-19 related challenges, we reported significant growth in our Revenue, EBITDA and PAT in FY21. All our sites remained operational throughout th
Slide 8: Financial Highlights (Pro-forma): Improvement in all Key Financial Parameters
Financial Highlights (Pro-forma2) : Improvement in all Key Financial Parameters ₹ 1,078 Cr. ₹ 203 Cr. 18.8% ₹ 95 Cr. 8.8% ₹ 6.0 Sales EBITDA EBITDA (%) PAT PAT (%) EPS Financial Highlights 31% YoY 101% YoY 652 bps 98% YoY 298 bps 98% YoY Q4’FY21 ₹ 823 Cr. ₹ 101 Cr. 12.3% ₹ 48 Cr. 5.9% ₹ 3.0 Sales-Q4
Slide 9: Jubilant Ingrevia: Business Segments & Integrated Operations
Jubilant Ingrevia: Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition & For Vitamin B3 (Niacinamide & Niacin), Life Science 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health H
Slide 10: Q4'FY21 Results Analysis
Q4'FY21 Results Analysis INGREVIA
Slide 11: Jubilant Ingrevia – Q4'FY21 Financial Highlights (Pro-forma)
Jubilant Ingrevia – Q4'FY21 Financial Highlights (Pro-forma2) • Revenue grew by 31% on YoY basis, driven by high single digit growth in volume Particulars1 Q4'FY20 Q4'FY21 YoY (%) and double digit growth in pricing Revenue • Speciality Chemicals revenue grew by 17% YoY driven by growth in Fine chemi
Slide 12: Specialty Chemicals: Market and Business Highlights
Specialty Chemicals: Market and Business Highlights - Overall demand continues to be strong. Domestic demand continues to improve due to shift of some of the Pharmaceutical & Agrochemical end products of customers from China to India Market - Paraquat ban in Brazil and Thailand resulted in lower dem
Slide 13: Speciality Chemicals Segment Highlights – Q4'FY21
Speciality Chemicals Segment Highlights – Q4'FY21 (Pro-forma2) Particulars1 Q4'FY20 Q4'FY21 YoY (%) Revenue 282 329 17% Specialty Chemicals revenue grew by 17% on YoY Reported EBITDA 64 69 9% basis driven by higher volume Reported EBITDA Margin (%) 22.6% 21.1% Speciality Chemicals revenue grew d
Slide 14: Nutrition & Health Solutions: Market and Business Highlights
Nutrition & Health Solutions: Market and Business highlights - During the year, there has been volatility in demand of Vitamin B3 (Niacinamide & Niacin) due to global pandemic situation, however during the quarter as market started opening in different parts of the world specially in Europe and USA,
Slide 15: Nutrition & Health Solutions Segment Highlights – Q4'FY21
Nutrition & Health Solutions Segment Highlights – Q4'FY21 (Pro-forma2) Particulars1 Q4'FY20 Q4'FY21 YoY (%) Nutrition and Health Solutions revenue grew by 22% Revenue 163 199 22% on YoY basis Reported EBITDA 39 43 9% • Growth was driven by double digit on volumes and Reported EBITDA Margin (%) 23.
Slide 16: Life Science Chemicals: Market and Business Highlights
Life Science Chemicals: Market and Business Highlights - Demand for Pharmaceutical products like Ibuprofen, Paracetamol ,Aspirin and others remained high across the globe driven by COVID-19 impact and this has helped in increased demand of Acetic Anhydride Market - Demand for Agrochemical products r
Slide 17: Life Science Chemicals Segment Highlights – Q4'FY21
Life Science Chemicals Segment Highlights – Q4'FY21 (Pro-forma2) Particulars1 Q4'FY20 Q4'FY21 YoY (%) Life Sciences Chemicals revenue grew by 46% on YoY basis Revenue 377 549 46% • Life Sciences Ingredients grew by higher double digit on YoY basis Reported EBITDA 15 105 589% • Life Sciences Chemic
Slide 18: FY21 Results Analysis
JUBUANT INGREVIA FY21 Results Analysis
Slide 19: Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma)
Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma2) Particulars1 FY20 FY21 YoY (%) • Revenue grew by 10% on YoY basis, driven by growth in volume Revenue Speciality Chemicals 1,104 1,124 2% and pricing together. Nutrition & Health Solutions 537 630 17% • Speciality Chemicals revenue g
Slide 20: Speciality Chemicals Segment Highlights – FY21
Speciality Chemicals Segment Highlights – FY21 (Pro-forma2) Particulars1 FY20 FY21 YoY (%) Specialty Chemicals revenue grew by 2% on YoY basis Revenue 1,104 1,124 2% driven by higher volume Reported EBITDA 237 268 13% Reported EBITDA Margin (%) 21.4% 23.9% Specialty Ingredient, Fine Chemicals an
Slide 21: Nutrition & Health Solutions Segment Highlights – FY21
Nutrition & Health Solutions Segment Highlights – FY21 (Pro-forma2) Particulars1 FY20 FY21 YoY (%) Nutrition and Health Solution revenue grew by 17% on Revenue 537 630 17% YoY basis Reported EBITDA 95 130 37% • Nutrition and Health Ingredients business grew in Reported EBITDA Margin (%) 17.7% 20.7
Slide 22: Life Science Chemicals Segment Highlights – FY21
Life Science Chemicals Segment Highlights – FY21 (Pro-forma2) Life Science Chemicals revenue grew by 13% on YoY basis Particulars1 FY20 FY21 YoY (%) Revenue 1,537 1,738 13% Life Sciences Ingredients Reported EBITDA 99 236 138% • Life Sciences Ingredients grew in double digit on YoY basis Reported
Slide 23: Debt Profile – Declining Leverage (Pro-forma)
Debt Profile – Declining Leverage (Pro-forma2) Leverage Net Debt to EBITDA Net Debt to Equity Consistent reduction in Net Debt to EBITDA 2.5 (Rs Crore) 1,295 ( x. Times ) ( x. Times ) 0.22 1,025 548 0.7 431 FY20 FY21 FY20 FY21 FY21 Gross Debt Net Debt Net Debt/EBITDA Net Debt/Equity Significant de
Slide 24: Balance Sheet – Key Parameters/Ratios (Pro-Forma)
Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 1.8x 2.0x 20.2% 16.4% 9.4% (%age) 12.0% (%age) 6.6% FY20 FY21 FY21 FY20 FY21 ROCE % Return on Equity Asset / Turnover ROA % Net Working Capital Operating C
Slide 25: Business outlook
Business outlook Demand scenario in all our business segments continue to be strong Given the strong demand and new customer acquisitions, we believe COVID-19 is not likely to have a material impact on our overall performance, provided the pandemic situation does not materially deteriorate going
Slide 26: Appendix
: Ww - JUBUANT INGREVIA — Appendix 26
Slide 27: Pro-Forma Income Statement Consolidated – Q4'FY21
Pro-Forma Income Statement Consolidated – Q4’FY21 (1 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited ) 1 Month 2 Month Particulars Q4 FY20 Q4 FY21 YoY (%) Q4FY21 Q4FY21 Revenue from operations a) Sales/Income from operations 810 3
Slide 28: Pro-Forma Income Statement Consolidated – FY21
Pro-Forma Income Statement Consolidated – FY21 (10 months discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months Jubilant Ingrevia Limited ) 10M'FY21 2M'FY21 Particulars1 FY20 FY21 YoY (%) Apr'20 to Jan'21 Feb'21 to Mar'21 Revenue from operations a) Sales/Income from operati
Slide 29: Combined Income Statement – Q4 & FY21 (Pro-Forma)
Combined Income Statement – Q4 & FY21 (Pro-Forma2) Particulars1 Q4'FY20 Q4'FY21 YoY (%) FY20 FY21 YoY (%) Total Revenue from Operations 823 1,078 31% 3,179 3,491 10% Speciality Chemicals 282 329 17% 1,104 1,124 2% Nutrition & Health Solutions 163 199 22% 537 630 17% Life Science Chemicals 377 549 46
Slide 30: For More Information
For More Information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Ph: +91 120 436 1002| 21 CDR India E-mail: hemant.bakhru@jubl.com Ph: +91 22 6645 1209 pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1034 Madison
Slide 31: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing 31